Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific
Cervical Carcinoma
M.D. Anderson Cancer Centermonoclonal_antibodyPhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
60 Active assets in the Cervical Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Carboplatin Advenchen Laboratories, LLC | Phase 3 | BB |
Hepatitis B Virus Vaccine Eunice Dube | Phase 4 | BB |
Gardasil 9 Vaccine Eunice Dube | Phase 4 | BB |
Pembrolizumab Mayo Clinic | Phase 2 | BB |
Nogitecan Advenchen Laboratories, LLC | Phase 3 | BB |
View all 50 →
Same molecule, other indications
Immunoglobulin Half-Ig G1-Kappa/Scfv-H-Ch2-Ch3, Anti-(Homo Sapiens Ctla4 (Cytotoxic T-Lymphocyte-Associated Protein 4, Cd152)) And Anti-(Homo Sapienspdcd1 (Programmed Cell Death 1, Pd-1, Pd1, Cd279)), Monoclonal Antibody, Bispecific is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →